MXPA05007496A - Thienopyrimidinediones and their use in the modulation of autoimmune disease. - Google Patents
Thienopyrimidinediones and their use in the modulation of autoimmune disease.Info
- Publication number
- MXPA05007496A MXPA05007496A MXPA05007496A MXPA05007496A MXPA05007496A MX PA05007496 A MXPA05007496 A MX PA05007496A MX PA05007496 A MXPA05007496 A MX PA05007496A MX PA05007496 A MXPA05007496 A MX PA05007496A MX PA05007496 A MXPA05007496 A MX PA05007496A
- Authority
- MX
- Mexico
- Prior art keywords
- ring
- thienopyrimidinediones
- nitrogen
- fluorine
- oxygen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to thienopyrimidinediones of formula (1) wherein R1 and R2 each independently represent a C1-6akyl, C3-6alkyl, C3-6alkenyl, C3-5cycloalkylC1-3alkyl or C3-6cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms R3 is a group CO-G or SO2-G where G is a 5- or 6-membered ring containing a nitrogen atom and a second heteroatom selected from oxygen and sulphur adjacent to the nitrogen; the ring being substituted by at least one group as defined in the specification, Q is CR4R5 where R4 is hydrogen, fluorine or C1-6 alkyl and R5 is hydrogen, fluorine or hydroxy; and Ar is a 5-10-membered aromatic ring system wherein up to 4 ring atoms may be heteroatoms independently selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more groups defined in the specification; as well as pharmaceutically acceptable salts and solvates thereof. Processes for their preparation of the compounds, pharmaceutical compositions containing them and their use in therapy, in particular in immunosuppression therapy are also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300119A SE0300119D0 (en) | 2003-01-17 | 2003-01-17 | Novel compounds |
| PCT/SE2004/000052 WO2004065394A1 (en) | 2003-01-17 | 2004-01-15 | Thienopyrimidinediones and their use in the modulation of autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05007496A true MXPA05007496A (en) | 2005-09-21 |
Family
ID=20290154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05007496A MXPA05007496A (en) | 2003-01-17 | 2004-01-15 | Thienopyrimidinediones and their use in the modulation of autoimmune disease. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7384951B2 (en) |
| EP (1) | EP1587812B1 (en) |
| JP (1) | JP4519121B2 (en) |
| KR (2) | KR101107486B1 (en) |
| CN (1) | CN100334093C (en) |
| AT (1) | ATE335748T1 (en) |
| AU (1) | AU2004206012B2 (en) |
| BR (1) | BRPI0406801B8 (en) |
| CA (1) | CA2512441C (en) |
| DE (1) | DE602004001857T2 (en) |
| EG (1) | EG25613A (en) |
| ES (1) | ES2270337T3 (en) |
| HK (1) | HK1081959A1 (en) |
| IL (1) | IL169370A (en) |
| IS (1) | IS2376B (en) |
| MX (1) | MXPA05007496A (en) |
| NO (1) | NO333702B1 (en) |
| NZ (1) | NZ541217A (en) |
| PL (1) | PL214682B1 (en) |
| RU (1) | RU2331647C2 (en) |
| SE (1) | SE0300119D0 (en) |
| UA (1) | UA81788C2 (en) |
| WO (1) | WO2004065394A1 (en) |
| ZA (1) | ZA200505364B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| US7393854B2 (en) * | 2003-01-17 | 2008-07-01 | Astrazeneca Ab | Thienopyrimidinedinones and their use in modulation of autoimmune disease |
| SE0300120D0 (en) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| SI1696920T1 (en) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| CA2608733A1 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| EP3088400A1 (en) | 2005-06-22 | 2016-11-02 | Plexxikon Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20081581A1 (en) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
| GB0713479D0 (en) * | 2007-07-11 | 2007-08-22 | Syngenta Participations Ag | Substituted aromatic heterocyclic compounds as fungicides |
| MX2010000617A (en) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
| WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
| PT2411395E (en) * | 2009-03-23 | 2013-06-06 | Glenmark Pharmaceuticals Sa | Furopyrimidinedione derivatives as trpa1 modulators |
| SG174403A1 (en) * | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
| SG173178A1 (en) | 2009-04-03 | 2011-09-29 | Hoffmann La Roche | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| JP2013510166A (en) | 2009-11-06 | 2013-03-21 | プレキシコン インコーポレーテッド | Compounds, methods and applications for kinase regulation |
| RS58455B1 (en) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (en) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
| US9296728B2 (en) | 2012-01-20 | 2016-03-29 | Regents Of The University Of Minnesota | Therapeutic compounds |
| US10085987B2 (en) | 2012-01-27 | 2018-10-02 | Thomas Jefferson University | MCT protein inhibitor-related prognostic and therapeutic methods |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| US9212178B2 (en) * | 2013-10-21 | 2015-12-15 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| EP3247360B1 (en) | 2015-01-22 | 2021-08-25 | The Scripps Research Institute | Heterocyclic inhibitors of monocarboxylate transporters |
| UY36586A (en) * | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | HETEROCICLILMETILTIENOURACILOS AND USE OF THE SAME |
| KR101712836B1 (en) * | 2016-03-17 | 2017-03-22 | 주식회사 골프존 | Apparatus for virtual golf simulation, method for image realization for virtual golf simulation and recording medium readable by computing device for recording the method |
| KR101712838B1 (en) * | 2016-03-17 | 2017-03-07 | 주식회사 골프존 | Apparatus for virtual golf simulation, method for image realization for virtual golf simulation and recording medium readable by computing device for recording the method |
| KR101730536B1 (en) * | 2016-03-17 | 2017-05-02 | 주식회사 골프존 | Method for contents transmission service in the screen golf system, control method of mobile terminal for contents transmission service and recording medium recording the method readable by computing device |
| TWI823932B (en) | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | Triazolopyrimidine compounds and their use in treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US738495A (en) * | 1902-12-26 | 1903-09-08 | William E Sherwood | Thill-coupling. |
| US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
| SE9702001D0 (en) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| JP2001525413A (en) | 1997-12-05 | 2001-12-11 | アストラゼネカ ユーケイ リミテッド | New compound |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| ES2211161T3 (en) * | 1998-08-28 | 2004-07-01 | Astrazeneca Ab | I HAVE (2,3-D) NOVEDOUS PYRIMIDINDIONAS, PROCEDURE FOR THE PREPARATION AND USE OF THEM IN THERAPY. |
| EP1280806B1 (en) * | 2000-05-04 | 2004-08-04 | AstraZeneca AB | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS |
| GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
| GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
| US7393854B2 (en) | 2003-01-17 | 2008-07-01 | Astrazeneca Ab | Thienopyrimidinedinones and their use in modulation of autoimmune disease |
| SE0300120D0 (en) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-01-17 SE SE0300119A patent/SE0300119D0/en unknown
-
2004
- 2004-01-15 WO PCT/SE2004/000052 patent/WO2004065394A1/en active IP Right Grant
- 2004-01-15 CN CNB2004800071073A patent/CN100334093C/en not_active Expired - Fee Related
- 2004-01-15 EP EP04702477A patent/EP1587812B1/en not_active Expired - Lifetime
- 2004-01-15 ES ES04702477T patent/ES2270337T3/en not_active Expired - Lifetime
- 2004-01-15 AU AU2004206012A patent/AU2004206012B2/en not_active Ceased
- 2004-01-15 US US10/542,197 patent/US7384951B2/en not_active Expired - Lifetime
- 2004-01-15 AT AT04702477T patent/ATE335748T1/en not_active IP Right Cessation
- 2004-01-15 KR KR1020057013126A patent/KR101107486B1/en active IP Right Grant
- 2004-01-15 NZ NZ541217A patent/NZ541217A/en not_active IP Right Cessation
- 2004-01-15 RU RU2005121494/04A patent/RU2331647C2/en not_active IP Right Cessation
- 2004-01-15 DE DE602004001857T patent/DE602004001857T2/en not_active Expired - Lifetime
- 2004-01-15 MX MXPA05007496A patent/MXPA05007496A/en active IP Right Grant
- 2004-01-15 BR BRPI0406801A patent/BRPI0406801B8/en not_active IP Right Cessation
- 2004-01-15 JP JP2006500750A patent/JP4519121B2/en not_active Expired - Fee Related
- 2004-01-15 KR KR1020117022785A patent/KR20110125256A/en not_active Application Discontinuation
- 2004-01-15 UA UAA200506377A patent/UA81788C2/en unknown
- 2004-01-15 PL PL378222A patent/PL214682B1/en unknown
- 2004-01-15 CA CA2512441A patent/CA2512441C/en not_active Expired - Lifetime
-
2005
- 2005-06-23 IL IL169370A patent/IL169370A/en active IP Right Grant
- 2005-07-01 ZA ZA2005/05364A patent/ZA200505364B/en unknown
- 2005-07-12 EG EGNA2005000380 patent/EG25613A/en active
- 2005-07-29 IS IS7965A patent/IS2376B/en unknown
- 2005-08-15 NO NO20053826A patent/NO333702B1/en not_active IP Right Cessation
-
2006
- 2006-02-17 HK HK06102161A patent/HK1081959A1/en not_active IP Right Cessation
-
2008
- 2008-05-05 US US12/115,171 patent/US20080214579A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05007496A (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease. | |
| ZA200505273B (en) | Novel compound | |
| MY138145A (en) | Thienopyrimidinediones and their use in the modulation of autoimmune disease | |
| HUP0402376A2 (en) | Imidazole-4-carboxamide derivatives, their preparation and pharmaceutical compositions suitable for treatment of obesity containing them | |
| HUP0101031A2 (en) | Bicyclo[2.2.1]heptanes and related compounds | |
| MXPA03011638A (en) | 4-piperazinylindole derivatives with 5-ht6 receptor affinity. | |
| HUP0401009A2 (en) | 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them | |
| MXPA05006420A (en) | Pyrimidine derivates for the treatment of abnormal cell growth. | |
| HUP0303756A2 (en) | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them | |
| NO305209B1 (en) | N-alkyl-2-substituted ATP analogs, such compounds for the preparation of therapeutics, pharmaceutical preparations containing such compounds, and their use | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| AU8794291A (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| HUP0402225A2 (en) | Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them | |
| NZ307505A (en) | Arylglycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds | |
| RS20050692A (en) | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | |
| HUP0401883A2 (en) | Muscarinic agonists and pharmaceutical compositions containing them | |
| HUP0003577A2 (en) | Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them | |
| EA200001101A1 (en) | NEW DIHYDROFURO [3,4-b] QUINOLIN-1-ONE, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
| HUP0402341A2 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| HUP0303593A2 (en) | Biguanide derivatives, pharmaceutical compositions containing them and their use | |
| DK0732332T3 (en) | Substituted benzothienylpiperazines, their use as drugs and their methods of preparation | |
| HUP0204217A2 (en) | Novel a-500359 derivatives | |
| EA200301171A1 (en) | NEW CONCENTRATIONS OF TRICYCLIC DIHYDROCHINOLINES, METHOD OF THEIR RECOVERY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA200101204A1 (en) | NEW BICYCLIC COMPOUNDS OF AMINOPYRASINONE, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |